2026-08-29T14:17:51Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/182972024-11-28T14:47:05Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16962col_20.500.12105_16973col_20.500.12105_16972
Repisalud author Fernández-Cidón, Bárbara author Candás-Estébanez, Beatriz author Gil-Serret, Miriam author Amigó, Núria author Corbella, Emili author Rodríguez-Sánchez, M. Ángeles author Padró-Miquel, Ariadna author Brotons, Carlos author Hernández-Mijares, Antonio author Calmarza, Pilar author Jarauta, Estibaliz author Brea, Angel J. author Mauri, Marta author Guijarro, Carlos author Vila, Àlex author Valdivielso, Pedro author Corbella, Xavier author Pintó, Xavier authoraffiliation [Fernández-Cidón,B; Candás-Estébanez,B; Padró-Miquel,A] Bioquímica Especial y Biología Molecular, Laboratori Clínic, Hospital Universitario de Bellvitge, L’Hospitalet de Ll., Spain. [Candás-Estébanez,B] Clinical Laboratory, SCIAS-Hospital de Barcelona, Barcelona, Spain. [Gil-Serret,M; Amigó,N] Biosfer Teslab, Reus, Spain. [Amigó,N] CIBERDEM, Universidad Rovira i Virgili, Tarragona, Spain. [Corbella,E; Rodríguez-Sánchez,MA; Corbella,X; Pintó,X] Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain. [Corbella,E; Pintó,X] Centro de Investigación Biomédica en Red, Fisiopatologia de la Obesidad y Nutrición CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. [Brotons,C] EAP Sardenya, Instituto de Investigaciones Biomédicas Sant Pau, Barcelona, Spain. [Hernández-Mijares,A] Hospital Universitario Dr. Peset, Valencia, Spain. [Calmarza,P; Jarauta,E] Servicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, CIBERCV IIS Aragón, Universidad de Zaragoza, Zaragoza, Spain. [Brea,AJ] Hospital General San Pedro, Logroño, Spain. [Mauri,M] Hospital de Terrassa (Consorci Sanitari de Terrassa), Terrassa, Spain. [Guijarro,C] Departamento de Esepecialidades Médicas y Salud Pública, Unidad de Medicina Interna, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, Alcorcón, Spain. [Vila,A] Hospital de Figueres (Fundació Salut Empordà), Figueres, Spain. [Valdivielso,P] Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Málaga, Spain. [Corbella,X] Facultad de Medicina y Ciencias de la Salud, Universitat Internacional de Catalunya, Barcelona, Spain. [Pintó,X] Department of Medicine, Campus Bellvitge, Universidad de Barcelona, L’Hospitalet de Ll., Spain. 2024-02-19T15:26:40Z 2024-02-19T15:26:40Z 2021-03-29 10.3390/jcm10071379 2077-0383 Journal of Clinical Medicine http://hdl.handle.net/10668/4588 33805580 http://hdl.handle.net/20.500.12105/18297 Some lipoprotein disorders related to the residual risk of premature cardiovascular disease (PCVD) are not detected by the conventional lipid profile. In this case-control study, the predictive power of PCVD of serum sdLDL-C, measured using a lipoprotein precipitation method, and of the physicochemical properties of serum lipoproteins, analyzed by nuclear magnetic resonance (NMR) techniques, were evaluated. We studied a group of patients with a first PCVD event (n = 125) and a group of control subjects (n = 190). Conventional lipid profile, the size and number of Very Low Density Lipoproteins (VLDL), Low Density Lipoproteins (LDL), High Density Lipoproteins (HDL) particles, and the number of particles of their subclasses (large, medium, and small) were measured. Compared to controls, PCVD patients had lower concentrations of all LDL particles, and smaller and larger diameter of LDL and HDL particles, respectively. PCVD patients also showed higher concentrations of small dense LDL-cholesterol (sdLDL), and triglycerides (Tg) in LDL and HDL particles (HDL-Tg), and higher concentrations of large VLDL particles. Multivariate logistic regression showed that sdLDL-C, HDL-Tg, and large concentrations of LDL particles were the most powerful predictors of PCVD. A strong relationship was observed between increased HDL-Tg concentrations and PCVD. This study demonstrates that beyond the conventional lipid profile, PCVD patients have other atherogenic lipoprotein alterations that are detected by magnetic resonance imaging (MRI) analysis. eng NMR analysis of lipoproteins Lipid profile Premature cardiovascular disease Residual cardiovascular risk Small dense LDL Lipoprotein particle number Lipoprotein precipitation Triglycerides Atherosclerosis Lípidos Enfermedades cardiovasculares Factores de riesgo de enfermedad cardiaca LDL-colesterol Lipoproteínas Triglycéridos Aterosclerosis Physicochemical Properties of Lipoproteins Assessed by Nuclear Magnetic Resonance as a Predictor of Premature Cardiovascular Disease. PRESARV-SEA Study research article